Bio Green Med Solution, Inc. quarterly report, Q1 FY2012

Full document

Business context and reporting period

The supplied filing identifies the registrant as Cyclacel Pharmaceuticals, Inc., not Bio Green Med Solution, Inc. This is Cyclacel’s unaudited Form 10-Q for the three months ended March 31, 2012. Cyclacel is a development-stage biopharmaceutical company focused on oncology; its lead candidate, sapacitabine, was in a Phase 3 AML trial, while it also marketed a small portfolio of products.

Financial performance and position

  • Revenue: $161,000, all product revenue, down 16% from $192,000 in Q1 2011. No collaboration, R&D, or grant revenue was recorded in either quarter.
  • Margins and expenses: Cost of goods sold was $94,000, or 58% of product revenue, versus 55% a year earlier; implied product gross margin was approximately 42%. R&D expense fell 56% to $1.347 million, primarily because Q1 2011 included a $1.6 million Daiichi Sankyo milestone. SG&A rose 11% to $1.996 million.
  • Losses: Operating loss was $3.276 million versus $4.800 million. Net loss was $2.955 million versus $4.588 million; net loss applicable to common shareholders was $3.137 million versus $4.770 million. Basic and diluted loss per share was $0.06 versus $0.10.
  • Cash flow: Operating cash use was $3.771 million, compared with $3.892 million. Investing activities provided $15,000; financing activities provided $2.945 million, principally from the March stock financing.
  • Liquidity: Cash and cash equivalents were $23.640 million at March 31, down $809,000 from year-end. Working capital was $18.370 million. Management estimated cash would fund working capital and ongoing sapacitabine trials for at least 12 months, but said further development and commercialization funding was uncertain.
  • Capital structure and liabilities: Total liabilities were $6.802 million and stockholders’ equity was $18.536 million. The balance sheet presents no conventional borrowings at quarter-end. Preferred stock had a $13.890 million aggregate liquidation preference. Common shares outstanding increased from 54.220 million at year-end to 58.993 million at March 31, partly reflecting the financing.

Changes, outlook, and material risks

  • On March 22, Cyclacel raised approximately $2.9 million net by issuing 4.688 million shares at $0.6476 per share. Investors also received rights to 10% of any future settlement relating to specified intellectual property, subject to a cap; the associated fair-value liability was $1.153 million at quarter-end.
  • The board elected not to declare the first-quarter cash dividend on its 6% convertible exchangeable preferred stock. The filing describes preferred dividends as cumulative.
  • Management expected 2012 R&D spending to increase versus 2011, excluding the prior-year milestone, as enrollment continued in the randomized SEAMLESS Phase 3 trial. It expected SG&A to remain around 2011 levels, ALIGN product sales to continue, and approximately $0.2 million of grant revenue over the next 12–18 months.
  • In a subsequent event, on May 15, 2012, Nasdaq approved continued listing under an exception through September 11, 2012, conditional on a closing bid of at least $1.00 for ten consecutive trading days. A reverse split was among the possible compliance measures discussed.
  • Risks include clinical-trial failure, delay or safety issues; an SPA does not guarantee FDA approval. Cyclacel reported ongoing patent litigation with Celgene; discovery was underway, with a jury trial scheduled to begin in June 2014. The litigation outcome and valuation assumptions could affect the Economic Rights liability and earnings.
  • Other risks include continued operating losses, dependence on additional financing or partners, concentrated product sales through three wholesalers, reliance on third-party manufacturers, foreign-exchange exposure without hedging, and potential patent and regulatory challenges. Management reported disclosure controls were effective as of March 31, 2012.

Important facts for investors to verify

  1. Confirm the issuer identity: the provided filing is for Cyclacel Pharmaceuticals, Inc., despite the request metadata naming Bio Green Med Solution, Inc.
  2. Check subsequent cash burn, available financing, and whether management’s stated 12-month runway remained adequate.
  3. Review SEAMLESS trial enrollment, results, costs, and any FDA or regulatory developments; the filing provides no trial outcome.
  4. Track Nasdaq bid-price compliance and any resulting listing or reverse-split action.
  5. Monitor the Celgene litigation, related potential settlement exposure, and the assumptions underlying the Economic Rights valuation.